• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Disc Medicine (IRON) Jumped, What Is Behind The Move?

    Simply Wall St·10/27/2026 00:44:12
    Listen to the news

    Disc Medicine (IRON) has drawn investor attention after announcing highly positive Phase 3 APOLLO data for bitopertin in erythropoietic protoporphyria, followed shortly by a US$450 million common stock offering priced at US$75 per share.

    Disc Medicine’s recent news arrives after a mixed run for holders, with a strong 30 day share price return of 19.04% and a softer year to date share price performance that is down 1.81%. The 3 year total shareholder return of 71.78% points to longer term momentum that has rewarded patient investors as the market reassesses the company’s growth prospects and risk profile following the APOLLO data and fresh equity raise.

    Capitalize on the momentum around Disc Medicine by scanning a curated list of biotech and healthcare stocks with resilient balance sheets and solid fundamentals via our list of solid balance sheet and fundamentals (24 results).

    Disc Medicine now trades at a heavy discount to both analyst targets and some intrinsic value estimates after the APOLLO surge and equity raise. Is that gap mispricing or a sober read on clinical and funding risk ahead?

    Most Popular Narrative: 33% Undervalued

    On the most followed view, Disc Medicine screens as materially undervalued, with a fair value of $116.67 against a last close of $77.66 that reflects both clinical promise and meaningful execution risk.

    The numbers on trial response rates, addressable patient pools in EPP and myelofibrosis anemia, and Disc Medicine's current cash runway to 2029 imply a share price that treats the company as having multiple potential blockbuster assets rather than a single asset story.

    See why 1 investors see Disc Medicine as 33% undervalued.

    Result: Fair Value of $116.67 (UNDERVALUED)

    Still, the Disc Medicine story can change quickly if regulators raise fresh questions around the bitopertin resubmission or if real world rare disease uptake proves slower than modeled.

    Find out about the key risks to this Disc Medicine narrative.

    Next Steps

    Mixed sentiment around Disc Medicine is clear. Check the data now, weigh the trade off between upside and threat, and review the 2 key rewards and 4 important warning signs.

    Looking for more investment ideas beyond Disc Medicine?

    If Disc Medicine has your attention right now, use that momentum to refresh your broader watchlist and line up your next set of potential opportunities.